Phase II induction therapy with docetaxel and carboplatin in NSCLC IIIA/IIIB: FDG-PET response predicts overall and disease free survival

ISSN

0169-5002

Date Issued

2005

Author(s)

Griesinger, Frank

Overbeck, Tobias R.

Schmidtberger, H.

Schirren, J.

Hemmerlein, Bernhard

Keppler, U.

Leupold, H.

Baum, R.

DOI

10.1016/S0169-5002(05)80201-6